Increased expression (at least two-fold higher) of immune checkpoint genes including PD-L1 (CD274), CTLA4, LAG3, and IDO1 was noted in ICI-treated patients compared to CRC all-comers, consistent with published literature [8,9]. The gene discussed is IDO1; the disease is colorectal carcinoma.